Search

Anemia treatments have greatly improved patient life expectancy in the past decade. However, few economic studies have evaluated the budgetary impact and cost effectiveness of these new therapies. The purpose of this study is to review published economic studies in severe red blood cell disorders, including autoimmune hemolytic anemia, beta-thalassemia, chemotherapy-induced anemia, chronic kidney disease anemia, and severe aplastic anemia to inform the conceptual framework for future economic research in severe anemia. [Extracted from the article]